Notably, the anti‐BP180 antibody levels correlate with the disease severity of bullous pemphigoid,3 allowing for disease monitoring and corticosteroid dosage adjustments based on antibody titers. This evidence concerns the gene COL17A1 and bullous pemphigoid.